27 reports

The global dementia drugs market was valued at approximately USD 12,736.06 million in 2020 and is expected to witness a revenue of USD 19,655.10 million in 2026, with a CAGR of 7.87% over the forecast period. The outbreak of the COVID-19 pandemic is expected to have a significant impact on the Dementia drugs market. According to a research...

  • Dementia
  • Pharmaceutical
  • Healthcare
  • World
  • Europe
  • North America
  • APAC
  • Dementia Prevalence
  • Health Expenditure

The Alzheimer’s disease diagnostics and therapeutics market was valued at USD 6,632.82 million in 2020, and it is expected to reach approximately USD 9,073 million in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026. The study titled, "Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a...

  • Dementia
  • World
  • Health Expenditure
  • Dementia Prevalence

Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Drugs In Development, 2022, provides an overview of the Mild Cognitive Impairment...

  • Dementia
  • World
  • Medicine Use
  • Pharmaceutical Production

Mild Cognitive Impairment (Central Nervous System) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Drugs In Development, 2021, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline...

  • Dementia
  • Drug Development
  • World
  • Pharmaceutical Registrations
  • Medicine Use

Mild Cognitive Impairment - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2020, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape. Mild cognitive...

  • Therapy
  • Dementia
  • World
  • Cause-Specific Mortality Rate
  • Depression Prevalence

Mild Cognitive Impairment - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2020, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape. Mild cognitive...

  • Dementia
  • World
  • Medicine Use
  • Cause-Specific Mortality Rate

INTRODUCTION Alzheimer’s disease is a neurodegenerative condition characterized by progressive memory loss, cognitive dysfunction and dementia. Currently, it is the most commonly reported neurodegenerative disorder across the world, and the sixth leading cause of death in the US. , It was estimated that, in 2018, nearly...

  • Dementia
  • World
  • Dementia Prevalence
  • Diagnostic Imaging Density

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2018 Summary Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving...

  • Dementia
  • World
  • Diagnostic Imaging Density
  • Prescription Drug Sales

Report Scope This research report presents an in-depth analysis of the global cognition and memory-enhancing drugs market by application, product categories, and regional markets.The report includes key cognition drugs that are incorporated in several therapeutic treatment methods. It discusses the role of supply...

  • Dementia
  • Research And Development
  • World
  • APAC

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H1 2018 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. The latest report Protein Kinase C Epsilon Type - Pipeline Review, H1 2018,...

  • Dementia
  • Neurological Disorder
  • World
  • Dropout Rate
  • Dementia Prevalence

Alzheimer’s Disease: Global Drug Forecast and Market Analysis to 2028 Summary Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline.During the early stages of the disease, sleep disturbances and forgetfulness...

  • Dementia
  • United States
  • World
  • China
  • Japan
  • Dementia Prevalence
  • Drug Approval

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H1 2018 Summary Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving...

  • Dementia
  • World
  • Diagnostic Imaging Density
  • Prescription Drug Sales

Cognitive and Memory Enhancer Drugs Market Cognitive enhancers are drugs and supplements, which are majorly used by patients suffering from Alzheimer’s disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. In addition, these drugs are used by health individuals to improve cognitive functions such as memory,...

  • Pharmaceutical
  • Dementia
  • Neurological Disorder
  • Stroke
  • Psychotic Disorder
  • World

Frontier Pharma: Alzheimer’s Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression Summary Alzheimer’s disease (AD) is the most common form of dementia - a generalized term used to describe...

  • Dementia
  • World
  • Dementia Prevalence
  • Diagnostic Imaging Density

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2026 Summary Alzheimer’s disease (AD) is a looming endangerment to global health, and a threat to the world economy. One in every three seniors in the US dies with AD or another form of dementia. It is the sixth leading...

  • Dementia
  • United States
  • Japan
  • United Kingdom
  • France
  • Germany
  • Spain
  • Italy
  • Elderly Population
  • Mortality Rate

Alzheimer’s disease is the most common cause of dementia among older people. It is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from Alzheimer’s disease is predicted...

  • Dementia
  • World
  • Dementia Prevalence
  • Drug Approval

Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016, provides an overview of the Dementia Associated With Alzheimer's Disease (Central Nervous...

  • Dementia
  • World
  • Drug Approval
  • Prescription Drug Sales

Lewy body Dementia - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Lewy body Dementia - Pipeline Review, H2 2016’, provides an overview of the Lewy body Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lewy body Dementia, complete...

  • Dementia
  • World
  • Diagnostic Imaging Density
  • Health Provider Density

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no treatments approved in this therapy area and five tauopathies are attracting increasing attention from pharmaceutical...

  • Dementia
  • Therapy
  • Clinical Trial
  • Biomarker
  • World
  • Drug Approval
  • Depression Prevalence

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment,...

  • Dementia
  • Drug Development
  • Therapy
  • World
  • Drug Approval
  • Cause-Specific Mortality Rate

Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2016’, provides an overview of the Dementia Associated With Alzheimer's Disease pipeline landscape. The report provides comprehensive information...

  • Dementia
  • World
  • Drug Approval
  • Pharmaceutical Registrations

Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies Summary Alzheimer’s Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and...

  • Dementia
  • APAC
  • Elderly Population
  • Health Insurance Coverage

Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents Summary Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional...

  • Dementia
  • World
  • Drug Approval
  • Life Expectancy

Executive Summary Progressive numbers of neurological disorders along with escalating demand for drugs to control of Alzheimer Disease. The Global Alzheimer’s Market is growing at a moderate rate over last five years on account of rising expenditure on health care especially neurological disorders among ageing population...

  • Dementia
  • World
  • Dementia Prevalence
  • Mortality Rate

Alzheimer's disease

4385 5000 3900

Amyloid-targeting immunotherapies may create a $10bn opportunity within the Alzheimer’s disease market. This report addresses the following questions: - How will the approval of immunotherapies affect Alzheimer’s disease treatment dynamics? - Which patient subgroups and drug class will have the largest impact on Alzheimer’s...

  • Dementia
  • United States
  • Japan
  • European Union
  • Dementia Prevalence
  • Mortality Rate

The objective of this report is to provide a detailed analysis of Alzheimer’s disease (AD) and the pharmaceutical drugs and medicinal plants used to treat and prevent it. It also provides an overview of the leading companies serving this market and their current and future product offerings. This report will prove useful for people...

  • Dementia
  • United States
  • World
  • Dementia Prevalence
  • Elderly Population

About neurodegenerative diseases According to the EU JPND, neurodegenerative diseases refer to conditions that involve the neurons in the brain. These conditions can affect balance, movement, speech, and respiratory and cardiac functions. They can be inherited or be of unknown etiology. Neurodegenerative diseases are incurable and are severely...

  • Neurological Disorder
  • Dementia
  • World
  • Drug Approval
  • Dementia Prevalence